Pain-relieving wound dressing after surgery for hidradenitis suppurativa
Tests a silver and lidocaine dressing after surgery in hidradenitis suppurativa.
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- Newark, United StatesSee the site
- Trial code
- Registry title
- Pelashield™ PainGuard™ vs Restrata® in HS Surgery
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 1 Dec 2025
- Expected to end
- Nov 2026
- Type of study
- Interventional
- Treatments tested
- Pelashield Painguard
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hidradenitis suppurativa (HS) who need wide surgery to remove the affected skin. It compares two wound coverings used after surgery.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Confirmed HS that needs wide surgical removal of affected skin
Main reasons for not taking part
- People who do not speak English, or cannot give consent in English
- Allergy to polyvinyl alcohol, local anesthetics, silver or lidocaine, or heart conditions that rule out lidocaine
- Pregnancy or breastfeeding
- Severely weakened immune system, for example chemotherapy within 3 months, a solid organ transplant, uncontrolled HIV with CD4 <200, or steroids >10 mg prednisone-equivalent/day
- Uncontrolled diabetes (HbA1c >10% (86 mmol/mol)), active body-wide infection or sepsis at surgery, or unable to attend follow-up visits through the second surgery
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults (≥18 years) with a confirmed clinical diagnosis of HS requiring wide surgical excision
- Ability to provide informed consent in English
- Willingness and ability to attend routine postoperative follow-up visits to monitor healing and readiness for second-stage closure
Who cannot take part
- Known allergy or hypersensitivity to wound matrix components (polyvinyl alcohol), local anesthetics, or silver
- Known sensitivity to lidocaine or history of cardiac conditions contraindicating lidocaine use (e.g., severe heart block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome)
- Severe immunosuppression (e.g., chemotherapy within 3 months, solid organ transplant, uncontrolled HIV with CD4 <200, or chronic systemic steroids >10 mg prednisone-equivalent/day)
- Active systemic infection or sepsis at time of surgery
- Uncontrolled diabetes (most recent HbA1c >10% if available within 3 months)
- Non-English-speaking patients (due to consent and follow-up communication limitations)
- Pregnancy or active breastfeeding
- Inability to complete postoperative follow-up through second-stage closure (e.g., plans to relocate)
Where in United States
- University HospitalNewark, United StatesContact: Mark Granick, MDTaking people
About the trial
What the trial wants to find out
Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal.
Read full original descriptionShow less
This study will compare two different wound matrices:
Restrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain.
The goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at:
How quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.
The group in the trial
- Pelashield™ PainGuard™ GroupTreatment being tested
Procedures: Perform wide excision of HS-affected tissue Apply Pelashield™ PainGuard™ to cover the surgical wound Place wound dressing and provide standard postoperative care instructions
Treatment: Pelashield Painguard
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Outcomes With Pelashield™ PainGuard™ Compared to Restrata® in Standard Two-Stage Excision and Closure for Hidradenitis Suppurativa: A Prospective Cohort With Retrospective Comparator
- Plain-language title
- Pain-relieving wound dressing after surgery for hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 22 May 2026